| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Division of Surgical Oncology and 2 Gastrointestinal Unit and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts and 3 Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts
Requests for reprints: James C. Cusack, Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, 7th Floor, Yawkey Building, 55 Fruit Street, Boston, MA 02114. Phone: 617-724-4093; Fax: 617-724-3895; E-mail: jcusack{at}partners.org or Fang Wang, Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Jackson Building 904, 55 Fruit Street, Boston, MA 02114. Phone: 617-726-5165; Fax: 617-726-8623; E-mail: fwang6{at}partners.org.
Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a member of the EGF growth factor family. Initially synthesized as a membrane-bound precursor (pro-HB-EGF), it is cleaved at the juxtamembrane domain to release the soluble form of HB-EGF (s-HB-EGF) by sheddases, including matrix metalloproteinases (MMP) and a disintegrin and metalloproteinases. This is a process referred to as ectodomain shedding and is implicated in the process of all ligands of the EGF receptor (EGFR) family. The tumorigenic potential of s-HB-EGF has been studied extensively; however, the role of pro-HB-EGF in tumor progression is unknown, despite the fact that a considerable amount of pro-HB-EGF remains on the cell membrane. Our data here clearly indicated the distinct role of pro-HB-EGF in the regulation of E-cadherin expression and the epithelial-mesenchymal transition. We showed here that the expression of pro-HB-EGF was associated with the differentiation status in pancreatic tumors and cell lines. Expression of noncleaved pro-HB-EGF in pancreatic cells resulted in the up-regulation of E-cadherin through suppression of ZEB1, which is a transcriptional repressor of E-cadherin. Inhibition of HB-EGF shedding using a MMP inhibitor, GM6001, also dramatically augmented the E-cadherin expression while suppressing the EGFR activation. Moreover, up-regulation of E-cadherin by pro-HB-EGF not only resulted in cellular morphologic change but also decreased cell motility and enhanced apoptotic sensitivity in response to gemcitabine-erlotinib treatment. Collectively, our data defined a distinct role of pro-HB-EGF in the regulation of E-cadherin, suggesting that inhibition of shedding may be a novel approach to suppress pancreatic metastasis and sensitize cells to cancer therapy. [Cancer Res 2007;67(18):8486–93]
This article has been cited by other articles:
![]() |
B. Urman, B. Ata, K. Yakin, C. Alatas, S. Aksoy, R. Mercan, and B. Balaban Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial Hum. Reprod., July 1, 2009; 24(7): 1640 - 1647. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Inuzuka, M. Tsuda, S. Tanaka, H. Kawaguchi, Y. Higashi, and Y. Ohba Integral Role of Transcription Factor 8 in the Negative Regulation of Tumor Angiogenesis Cancer Res., February 15, 2009; 69(4): 1678 - 1684. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yagi, F. Yotsumoto, and S. Miyamoto Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition Mol. Cancer Ther., October 1, 2008; 7(10): 3441 - 3451. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |